Capital World Investors Reduces Stake in Exact Sciences

Institutional investor cuts position in medical research company by 11.3% in Q3

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Capital World Investors, a major institutional investor, reduced its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 11.3% during the third quarter of 2025. The firm now owns 16,140,861 shares, or 8.52% of the medical research company's stock, valued at $883,053,000.

Why it matters

This reduction in ownership by a prominent institutional investor could signal a shift in sentiment around Exact Sciences, which develops cancer screening tests like the Cologuard DNA test. The stock price and trading volume of EXAS may be impacted by this change in a major shareholder's position.

The details

According to a regulatory filing, Capital World Investors sold 2,059,161 shares of Exact Sciences during the third quarter. The firm remains a significant shareholder, owning 8.52% of the company's outstanding stock. Exact Sciences is focused on developing innovative cancer detection and prevention technologies.

  • Capital World Investors reduced its Exact Sciences stake during Q3 2025.

The players

Capital World Investors

A major institutional investment firm that owns a sizable stake in Exact Sciences Corporation.

Exact Sciences Corporation

A medical research company focused on developing cancer screening and prevention technologies, including the Cologuard DNA test.

Got photos? Submit your photos here. ›

The takeaway

This reduction in ownership by a prominent Exact Sciences shareholder could signal a shift in sentiment around the company and its cancer detection products. Investors will be watching to see if other institutional investors follow suit or if Capital World Investors continues to reduce its position further.